68 results about "Herpes simplex virus infection" patented technology

The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intraoellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-α-tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses. Together the components of this invention provide the potential for improved resistance to, improved recovery from, and a decreased frequency of recurrence of herpes simplex virus infection.

The present invention relates to a preparation method for a blattodea polypeptide substance, and a medical use of the blattodea polypeptide substance in anti-herpesvirus. Specifically the present invention relates to a blattodea extract effective fraction having a function of prevention and treatment of herpes simplex virus infection diseases, a preparation method and a medical use thereof. The Periplaneta Americana extract effective fraction of the present invention is a polypeptide substance with a molecular weight less than 5000 dalton, and is prepared by the following steps: carrying out extraction on fresh polypide or dried polypide of Periplaneta Americana with water or an organic solvent and a buffer, and then carrying out a membrane separation method to refine to obtain the product of the present invention, wherein the polypeptide active substance of the effective fraction has significant anti-herpes simplex virus (HSV-1 and HSV-2) activities, can be prepared into forms of a hydrogel, a cataplasm, lyophilized powder, a water agent, an aerosol, a suppository, a film agent, an external application liniment, and an ointment, and can be used for preparations of drugs for prevention and treatment of herpes simplex virus infections, daily chemical products or medical devices.

The present invention relates to a dandelion plant phenolic acid effective component for preventing and curing herpes simplex virus infection and its application in preparation of medicine for preventing and curing ulcerative stomatitis. The invented dandelion plant phenolic acid effective component is obtained by using fresh dandelion plant or dried dandelion plant and making it undergo the processes of alcohol and water extraction, column chromatography and alcohol solvent elution, etc. Said effective component can be made into lozenge, powder preparation, spray, granules and oral solution, etc.

Rupestonic acid derivatives are rupestonic acid derivative A- or B-type compounds, prepared through a condensation reaction from starting materials, i.e., a monomer compound of rupestonic acid and an aromatic amine or fatty amine or an organic alcohol, i.e., a fatty alcohol or an aromatic alcohol. Rupestonic acid, which is the monomer compound of sesquiterpene isolated from the plant Xinjiang Artemisia rupestric L., is used as a mother compound. Natural anti-virus lead compound with high activity are discovered by modifying the structure of the monomer compound of rupestonic acid. Activity results of the lead compound showed pharmaceutical application of anti-I, II flu virus and anti-I, II herpes simplex virus infection. These compounds can be used alone or in combination with one or more pharmaceutical acceptable, inert and nontoxic excipients or carries in a pharmaceutical composition.

The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.

A composition and method for oral application to mouth tissue to reduce the symptoms of herpes simplex virus infection, said composition comprising an anti-viral agent, an antioxidant agent, an analgesic agent and a flavorant.

The invention discloses houttuynoids and a preparation method and application thereof. The houttuynoids have a structural formula as represented by formula (I) which is described in the invention; in the formula (I), R1 is represented by formula (I), formula (II), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX) or formula (X) as described in the invention, and R2 is hydrogen or is represented by formula (XI), formula (XII), formula (XIII) or formula (XIV) as described in the invention. 12 houttuynoids are separated from Saururaceae Houttuynia cordata Thunb. and are all furan-flavones with novel structures. An in-vitro anti-herpes simplex virus activity screening system is used for evaluating activity of the houttuynoids, and it is found that the houttuynoids can effectively inhibit a herpes simplex virus; thus, the houttuynoids have effects on preventing and treating herpes simplex virus infection, can be applied to preparation of drugs used for resisting the herpes simplex virus and have good research and development prospects.

The invention discloses application of nucleoside type antiviral medicine to preparation of medicine for treating infarction diseases, relates to the technical field of medicine, and aims at providinga novel direction for researching and developing the medicine for treating the infarction diseases. According to the application of the nucleoside type antiviral medicine to preparation of the medicine for treating the infarction diseases provided by the invention, the nucleoside type antiviral medicine can reduce the serious degree and the frequency of herpes simplex virus infection, and also has the significant activity of relieving infarction complications. Studies prove that in the infarction diseases, blood platelet adhesion, activation and aggregation achieve the key regulating effects;the nucleoside type antiviral medicine, such as famciclovir can inhibit the blood platelet aggregation, inhibit the GPIIb / IIIa activation, inhibit P-selectin expression and / or inhibit arteriovenous thrombus and cerebral infarction formation; meanwhile, a blood coagulation system is not influenced; and a novel idea is provided for the research and development of medicine for treating the infarction diseases.

The invention provides a herpes simplex virus type 1 and type 2 typing nucleic acid detection kit which includes a PCR reaction solution 1, a PCR reaction solution 2, negative control and positive control. The PCR reaction solution 1 is prepared from a HSV-1 type upstream primer, a downstream primer, a fluorescent probe, a HSV-2 type upstream primer, a downstream primer, a fluorescent probe, DNA polymerase, uracil DNA glycosylase, dNTP, a PCR buffer, a PCR amplification enhancer, an antiseptic agent and water; and the PCR reaction solution 2 is prepared from manganese acetate, an antiseptic agent and water. The herpes simplex virus type 1 and type 2 typing nucleic acid detection kit is convenient to operate, the reagent is stored at 2-8 DEG C, the detection sensitivity is high, the specificity is good, the repeatability is high, and the detection result is fast. The herpes simplex virus type 1 and type 2 typing nucleic acid detection kit can be used to simultaneously perform typing fluorescence PCR qualitative detection on specific DNA nucleic acid fragments of herpes simplex virus type 1 and type 2 in a single tube, a reliable molecular diagnostic basis is provided for diagnosingherpes simplex virus infection.

An assay for infection with one or more herpes simplex viruses that comprises a) dividing an antibody-containing serum sample into at least three serum subsamples, and b) separately incubating each with a physical matrix of cell antigens from i) uninfected cells, (ii) HSV-1-infected cells, or (iii) HSV-2-infected cells to form at least three serum subsample admixtures so that antibodies present in each admixture can immunoreact to form matrix-bound antibodies and at least three preadsorbed serum subsample portions. Each preadsorbed serum subsample portion is incubated with a mixture of matrix-bound antigens from cells uninfected by HSV-1 or HSV-2, infected by each of HSV-1 and by HSV-2 to permit antibodies to immunoreact with antigens present to form three matrix-bound immunoreactants. The amount of each immunoreaction is determined, and reaction amounts are prognostic for whether the subject whose serum was tested is infected by one, both, or neither of HSV-1 and HSV-2.

The present invention includes methods for the treatment of a herpes simplex virus infection comprising the administration of inhibitors of gamma interferon, tumor necrosis alpha and interleukin-1.

The invention relates to a sulphonated Gleditia sinensis Lam polysaccharide with bioactivity and application thereof. The sulphonated Gleditia sinensis Lam polysaccharide is characterized in that a polysaccharide chain contains galactose and mannose, a main chain is D-mannopyranose connected through a beta-(1,4)-glucosidic bond, a branched chain is D-galactopyranose connected through an alpha-(1,6)- glucosidic bond, and the degree of esterification is between 0.1 and 1.7. The sulphonated Gleditia sinensis Lam polysaccharide provided by the invention is obtained by utilizing a sulphonating agent to process a hot water extract of Gleditia sinensis Lam; and the sulphonating method thereof comprises the following steps: adding Gleditia sinensis Lam polysaccharide into the sulphonating agent, reacting while controlling the temperature and stirring, taking out a flask after the reaction is finished, cooling to room temperature, neutralizing by utilizing a NaOH solution, carrying out precipitating and washing for several times by utilizing ethanol, carrying out dialysis in distilled water, carrying out reduced pressure distillation on the dialysate, precipitating by utilizing absolute ethyl alcohol, and drying the precipitation in vacuum to obtain the sulphonated Gleditia sinensis Lam polysaccharide, wherein the sulphonating agent consists of chlorosulfonic acid and formamide or pyridine at the volume ratio of 1:5-10. The sulphonated Gleditia sinensis Lam polysaccharide obtained in the invention has higher substitution degree, stronger activity for resisting human AIDS viruses and herpes simplex viruses and low toxicity to human cells, and can be used for preparing a preparation of preventing or curing human AIDS virus and herpes simplex virus infection.

Provided are anti-heparan sulfate peptides and methods that employ those peptides for the prevention or treatment of viral infections, including herpesviral infections such as α-herpesviral, β-herpesviral, and γ-herpesviral infections, which are exemplified by HSV-1. CMV, and HHV-8 viral infections, respectively. Peptides may comprise at least 10 amino acids of the amino acid sequences XRXRXKXXRXRX (SEQ ID NO: 2), XRXRXXKXRXRX (SEQ ID NO: 8), XXRRRRXRRRXK (SEQ ID NO: 4), and / or KXRRRXRRRRXX (SEQ ID NO: 10), wherein X represents any amino acid. In some embodiments, peptides comprise at least 10 amino acids of the sequence LRSRTKIIRIRH (SEQ ID NO: 1), HRIRIIKTRSRL (SEQ ID NO: 7), MPRRRRIRRRQK (SEQ ID NO: 3), and / or KQRRRIRRRRM (SEQ ID NO: 9). Peptides may be coupled to one or more therapeutic compound(s) to generate peptide-therapeutic compound conjugates, wherein the therapeutic compound may be one or more of a nucleoside analog, an oligosaccharide, and a small molecule.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the same, and further relates to a kit comprising the hybridoma cell strain or the monoclonal antibody. The monoclonal antibody can specifically bind with human IgM, can be used for invitro detecting of the human IgM and is especially suitable for being used for early diagnosis of herpes simplex virus infection.

The present invention pertains to a composition for preparing a medicament for preventing and / or treating a virus infection, especially a hepatitis B virus infection and / or a herpes simplex virus, and uses thereof.

The invention relates to a medicine for treating herpes simplex virus infection, belongs to the technical field of medicines, and aims at solving the problem of treatment of the herpes simplex virus infection. The medicine is mainly prepared from the following traditional Chinese medicines in parts by weight: 10 parts of mung bean, 20 parts of honeysuckle, 15 parts of dried radix rehmanniae, 15 parts of spina gleditsiae, 15 parts of mulberry leaves, 15 parts of pericarpium citri reticulatae viride, 15 parts of folium isatidis, 15 parts of radix achyranthis bidentatae, 15 parts of radix isatidis, 10 parts of lalang grass rhizome, 10 parts of seaweeds and 7 parts of liquorice. According to the medicine for treating the herpes simplex virus infection, the traditional Chinese medicines capable of clearing the lung, cooling the blood, activating blood circulation, clearing away heat and toxic materials, removing wind and reducing phlegm for treatment are combined, so that an obvious treatment effect is obtained.

The invention provides new methods of preventing and / or treating herpes virus infections, particularly reducing infection, one or more symptoms and recurrence of one or more symptoms of herpes simplex virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being exposed to alphaherpesvirinae, has been exposed to alphaherpesvirinae or is infected with alphaherpesvirinae. The ISS is administered without any alphaherpesvirinae antigens. Administration of the ISS results in reduced incidence, recurrence, and severity of one or more symptoms of alphaherpesvirinae infection

Tetrahydronaphthyridines of formulaare disclosed. These compounds selectively inhibit αVβ3 without activating the αVβ3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing αVβ3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.

The present invention relates to an application of Chinese medicine preparation for curing trichomonad and pathogen infection in the preparation of medicine for curing influenza virus and herpes simplex virus infection. Said invention uses forsythia fruit volatile oil and borneol as prescription medicine, and adds the auxiliary solvent to make them into liniment or injection or suppository. Said medicine series can be used for curing influenza, genital herpes, herpes labialis and tinea manuum and tinea pedis, etc.

The invention provides application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus. Experiments prove that the myricetin hasthe inhibitory activity on herpes simplex virus infection, has the activity of resisting HSV-1 and HSV-2, and has extremely low toxicity. The protein and mRNA expression of HSV-1 and HSV-2 were significantly inhibited by myricetin treatment. The action mechanism of the myricetin for resisting herpes simplex virus infection is that the myricetin directly interacts with HSV particles to interfere virus adsorption and virus-induced membrane fusion. Experiments prove that the myricetin can be developed into a novel target virus particle anti-HSV preparation and has good market application prospect.

A method of treating herpes simplex virus infection or varicella zoster virus infection is disclosed. The method includes topically applying a composition containing an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds or milbemycin compounds and a pharmaceutically acceptable carrier to the affected area of an individual suffering from herpes simplex virus infection or varicella zoster virus infection.

A pharmaceutical composition or a health functional food composition for preventing or treating Behcet's disease have Tetragenococcus halophilus, a culture thereof or a lysate thereof. In addition, a pharmaceutical composition or a health functional food composition for preventing or treating a herpes simplex virus infection have Tetragenococcus halophilus, a culture thereof or a lysate thereof. The composition may further include a prebiotic compound. The Tetragenococcus halophilus produces lactate, and the lactate can be converted into short-chain fatty acids such as butyrate in the body, can control the expression of activating molecules of dendritic cells, and can effectively prevent or treat Behcet's disease or herpes simplex virus infection.

The invention relates to an isatis root, lucid ganoderma and rhodiola composition capable of improving microcirculation and preparations thereof. The composition is composed of 25-35 parts of isatis roots, 20-30 parts of lucid ganoderma, 10-25 parts of rhodiola, 0-10 parts of liquorice and 0-5 parts of wormwood. The preparations such as external use liquid medicine, external unguent, internal instant herbal medicine, granules, powder, tablets, capsules, water pill agents and concentrated soluations are formed through a common extraction technology. According to the isatis root, lucid ganoderma and rhodiola composition, the isatis roots are matched with the lucid ganoderma and the rhodiola appropriately. The composition is safe, free of toxicity and capable of being used for cold prevention, herpes simplex virus infection resisting, burn and scald treatment and treatment of other acute diseases; the composition can also be used for a long term, the human body microcirculation improving effects such as toxin generation restraining and harmful metabolite removing can further be achieved, and the effect that one drug can be used for treating various diseases and the anti-aging effect are achieved.

The invention provides application of sophoridine in preparation of anti-herpes virus drugs, and belongs to the field of pharmacy. Experimental results show that sophoridine can effectively inhibit formation of HSV-1 virus plaques and significantly inhibit generation of filial generation viruses; the sophoridine can also significantly inhibit the expression levels of gB and gD proteins of the HSV-1 virus, and significantly inhibit the expression levels of UL27 and US6 genes. The sophoridine has a remarkable inhibiting effect on the growth of the herpes simplex virus type 1, can be used for preparing the medicine for resisting the herpes simplex virus type 1, and can also be used for preparing the medicine for treating the infectious diseases of the herpes simplex virus type 1. In addition, sophoridine has low toxicity to normal cells, and has wide application prospects in preparation of anti-herpes virus drugs and drugs for prevention and treatment of herpes virus infection diseases.